| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | 21066 |
| Drug | Osimertinib |
| Brand | Tagrisso® |
| Indication | For adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA Non-Small Cell Lung Cancer whose tumour has epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations. |
| Assessment Process | |
| Rapid review commissioned | 20/12/2021 |
| Rapid review completed | 13/01/2022 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of osimertinib compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 31/01/2022 |
| Pre-submission consultation with Applicant | 15/03/2022 |
| Full submission received from Applicant | 16/08/2022 |
| Preliminary review sent to Applicant | 27/01/2023 |
| NCPE assessment re-commenced | 13/03/2023 |
| Factual accuracy sent to Applicant | 03/05/2023 |
| NCPE assessment re-commenced | 10/05/2023 |
| NCPE assessment completed | 23/05/2023 |
| NCPE assessment outcome | The NCPE recommends that osimertinib not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
